Worth reading
45Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
3.6
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter1 July 2025 to 31 March 2026ConsolidatedJapanese GAAPNet Sales95,777¥ millionYear on year +3.6%Progress 74.8%
Operating profit1,244¥ millionYear on year -3.8%Progress 62.2%
Ordinary income1,236¥ millionYear on year -3.8%Progress 64.1%
Net income attributable to owners of the parent872¥ millionYear on year -6.5%Progress 66.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥147.12
Financial position at period-end
Total assets49,360¥ million
of which net assets 12,563 ¥ millionEquity ratio 25.5%vs. prior year-end -1.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueRevenue from external customers ¥89,174,545 thousand (YoY +3.4%), Revenue from external customers ¥4,430,895 thousand (YoY +6.8%), Revenue from external customers ¥2,172,175 thousand (YoY +5.3%)
Segment profitMedical Equipment Business ¥1,064,780 thousand (YoY -7.6%), SPD business ¥81,613 thousand (YoY -9.2%), Care Products Business ¥189,111 thousand (YoY +32.7%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥127,978 million (YoY +4.3%)
Operating profit¥2,000 million (YoY +1.0%)
Ordinary income¥1,928 million (YoY -1.7%)
Net income¥1,321 million (YoY -7.6%)
Revision to Earnings ForecastNo revision
Annual Dividend Forecast¥80 → ¥80（0.0%）
Factors Behind Changes in Business Performance
Net sales increased due to higher sales of consumables in the Medical Equipment business, an increase in contracts in the SPD business and demand for rentals in the Nursing Care Products business. However, the Company was unable to fully pass higher procurement costs on to selling prices, while selling, general and administrative expenses increased due to salary base increases, additional personnel and system investments in OLBA-DX, resulting in a decline in operating income.
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Impairment lossNo applicable matters
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of property, plant and equipment ¥131,684 thousand, Gain on sale of investment securities ¥99 thousand / Extraordinary loss Loss on disposal of property, plant and equipment ¥1,519 thousand, Loss on sale of property, plant and equipment ¥19,602 thousand, Loss on disposal of intangible assets ¥82 thousand
Depreciation and amortization¥542,393 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End6,250,000
Treasury Shares at Period-End321,972
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2025 to 31 March 2026 |
| Net Sales | ¥95,777 million (YoY +3.6%) |
| Operating profit | ¥1,244 million (YoY -3.8%) |
| Ordinary income | ¥1,236 million (YoY -3.8%) |
| Profit attributable to owners of the parent | ¥872 million (YoY -6.5%) |
| Net income per share | ¥147.12 |
| Equity ratio | End of the current fiscal period 25.5 / End of previous period 26.7 |
| Total assets | ¥49,360 million |
| Net assets | ¥12,563 million |
| Full-year earnings forecast | Net Sales ¥127,978 million (YoY +4.3%) / Operating profit ¥2,000 million (YoY +1.0%) / Ordinary income ¥1,928 million (YoY -1.7%) / Net income ¥1,321 million (YoY -7.6%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥80 → ¥80（0.0%） |
| Segment revenue | Revenue from external customers ¥89,174,545 thousand (YoY +3.4%), Revenue from external customers ¥4,430,895 thousand (YoY +6.8%), Revenue from external customers ¥2,172,175 thousand (YoY +5.3%) |
| Segment profit | Medical Equipment Business ¥1,064,780 thousand (YoY -7.6%), SPD business ¥81,613 thousand (YoY -9.2%), Care Products Business ¥189,111 thousand (YoY +32.7%) |
| Depreciation and amortization | ¥542,393 thousand |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of property, plant and equipment ¥131,684 thousand, Gain on sale of investment securities ¥99 thousand / Extraordinary loss Loss on disposal of property, plant and equipment ¥1,519 thousand, Loss on sale of property, plant and equipment ¥19,602 thousand, Loss on disposal of intangible assets ¥82 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 6,250,000 |
| Treasury Shares at Period-End | 321,972 |
| Factors Behind Changes in Business Performance | Net sales increased due to higher sales of consumables in the Medical Equipment business, an increase in contracts in the SPD business and demand for rentals in the Nursing Care Products business. However, the Company was unable to fully pass higher procurement costs on to selling prices, while selling, general and administrative expenses increased due to salary base increases, additional personnel and system investments in OLBA-DX, resulting in a decline in operating income. |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although net sales increased, mainly in the Medical Equipment business, the Company was unable to fully pass higher procurement costs on to selling prices. Selling, general and administrative expenses also increased due to salary base increases, additional personnel and system investments.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.